

## SUPPLEMENTARY MATERIAL

### P450 enzymes mainly involved in the metabolism of antidepressants prescribed in our sample

<b>Antidepressant</b>	<b>CYP enzymes</b>
<i>Sertraline</i>	CYP2C19 CYP2B6
<i>Paroxetine</i>	CYP2D6
<i>Escitalopram</i>	CYP2C19 CYP2D6 CYP3A4
<i>Citalopram</i>	CYP2C19 CYP2D6 CYP3A4
<i>Fluoxetine</i>	CYP2D6 CYP2C9
<i>Venlafaxine</i>	CYP2D6
<i>Duloxetine</i>	CYP1A2 CYP2D6

## Main socio-demographic and clinical characteristic of our sample

Variable	Frequency [N(%)]	Psychiatric comorbidity	
<b>Total sample</b>	87 (100)	Yes	21 (24.1)
<b>Nationality</b>		<b>Organic comorbidity</b>	
Italian	69 (79.3)	Yes	13 (14.9)
Other	18 (20.7)	<b>Other medications</b>	
<b>Marital Status</b>		Non psychiatric	22 (25.3)
Married	37 (42.5)	Benzodiazepines	11 (12.6)
Unmarried	39 (44.8)	S-adenosylmethionine infusive therapy	5 (5.7)
Single	3 (3.5)	<b>Active tobacco use</b>	
Unknown	8 (9.2)	Yes	11 (12.6)
<b>Education</b>		<b>Active alcohol use</b>	
Primary School	0 (0)	Yes	1 (1.2)
Secondary School	10 (11.5)	<b>Current antidepressant</b>	
High School	33 (37.9)	Sertraline	43 (49.5)
University	28 (32.2)	Paroxetine	13 (14.9)
Unknown	16 (18.4)	Escitalopram	11 (12.6)
<b>Occupation</b>		Citalopram	3 (3.5)
Employed	35 (40.2)	Fluoxetine	4 (4.6)
Unemployed	8 (9.2)	Venlafaxine	11 (12.6)
Unknown	44 (50.6)	Duloxetine	2 (2.3)
<b>Diagnosis</b>		<b>Metabolic profile</b>	
Major depressive disorder	39 (44.8)	Poor	5 (7)
Anxiety disorder	36 (41.4)	Intermediate	17 (24)
Obsessive-compulsive disorder	7 (8.0)	Extensive	39 (61,9)
Bipolar disorder type II	4 (4.6)	Ultra rapid	10 (7,1)
Post-traumatic stress disorder	1 (1.2)	Missing	16

